Literature DB >> 25748305

Streamlining deep brain stimulation surgery by reversing the staging order.

Craig G van Horne1, Scott W Vaughan, Carla Massari, Michael Bennett, Wissam S Z Asfahani, Jorge E Quintero, Greg A Gerhardt.   

Abstract

Deep brain stimulation (DBS) is approved for several clinical indications; however, the sequencing of DBS surgery and the timeline for implementing stimulation therapy are not standardized. In over 140 cases so far, the authors have reversed the sequencing for staged implantation of DBS systems that was conducive to minimizing patient anxiety and discomfort while providing the opportunity to shorten the time between implantation and programming for therapeutic management of symptoms. Stage I was performed with the patient under general anesthesia and consisted of implantation of the pulse generator and lead extensions and placement of the bur holes. Stage II was completed 1-7 days later, using only local anesthesia, and included stereotactic frame-based microelectrode recordings, semi-microstimulation and macrostimulation, and testing and placement of the stimulating electrodes. Stage I lasted approximately 90 minutes, whereas Stage II lasted approximately 230 minutes. All patients tolerated the procedures and received a complete implanted system. Deep brain stimulation therapy was typically initiated on the same day as lead implantation. When sequencing was reversed and bur holes were placed during the first stage while a patient was under general anesthesia, the patient was able to tolerate the second awake stage and was able to begin stimulation therapy within 48 hours of the second stage.

Entities:  

Keywords:  CRW = Cosman-Roberts-Wells; DBS = deep brain stimulation; anesthesia; deep brain stimulation; functional neurosurgery; neuronavigation

Mesh:

Year:  2015        PMID: 25748305     DOI: 10.3171/2014.9.JNS14619

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  Direct delivery of an investigational cell therapy in patients with Parkinson's disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design.

Authors:  Jorge E Quintero; John T Slevin; Julie A Gurwell; Christopher J McLouth; Riham El Khouli; Monica J Chau; Zain Guduru; Greg A Gerhardt; Craig G van Horne
Journal:  BMJ Neurol Open       Date:  2022-07-14

2.  RNA Sequencing of Human Peripheral Nerve in Response to Injury: Distinctive Analysis of the Nerve Repair Pathways.

Authors:  Andrew S Welleford; Jorge E Quintero; Nader El Seblani; Eric Blalock; Sumedha Gunewardena; Steven M Shapiro; Sean M Riordan; Peter Huettl; Zain Guduru; John A Stanford; Craig G van Horne; Greg A Gerhardt
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

3.  Single-Stage Deep Brain Stimulator Placement for Movement Disorders: A Case Series.

Authors:  Arrin Brooks; Alastair T Hoyt
Journal:  Brain Sci       Date:  2021-05-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.